These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1443 related articles for article (PubMed ID: 32714324)

  • 1. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
    Zhang C; Liu Y
    Front Immunol; 2020; 11():1295. PubMed ID: 32714324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NK Cell Dysfunction and Checkpoint Immunotherapy.
    Bi J; Tian Z
    Front Immunol; 2019; 10():1999. PubMed ID: 31552017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NK Cell-Based Immune Checkpoint Inhibition.
    Khan M; Arooj S; Wang H
    Front Immunol; 2020; 11():167. PubMed ID: 32117298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy.
    Sun H; Sun C
    Front Immunol; 2019; 10():2354. PubMed ID: 31681269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.
    Cao Y; Wang X; Jin T; Tian Y; Dai C; Widarma C; Song R; Xu F
    Signal Transduct Target Ther; 2020 Oct; 5(1):250. PubMed ID: 33122640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells.
    Pesce S; Greppi M; Grossi F; Del Zotto G; Moretta L; Sivori S; Genova C; Marcenaro E
    Front Immunol; 2019; 10():1242. PubMed ID: 31214193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors.
    Li Y; Zhang Y; Cao G; Zheng X; Sun C; Wei H; Tian Z; Xiao W; Sun R; Sun H
    J Hematol Oncol; 2021 Jun; 14(1):100. PubMed ID: 34174928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.
    Zhang Q; Bi J; Zheng X; Chen Y; Wang H; Wu W; Wang Z; Wu Q; Peng H; Wei H; Sun R; Tian Z
    Nat Immunol; 2018 Jul; 19(7):723-732. PubMed ID: 29915296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
    Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
    Front Immunol; 2020; 11():7. PubMed ID: 32117218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
    Shaver KA; Croom-Perez TJ; Copik AJ
    Front Immunol; 2021; 12():679117. PubMed ID: 33995422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
    Ge Z; Peppelenbosch MP; Sprengers D; Kwekkeboom J
    Front Immunol; 2021; 12():699895. PubMed ID: 34367161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Natural Killer Cells for Tumor Immunotherapy.
    Zhang C; Hu Y; Shi C
    Front Immunol; 2020; 11():60. PubMed ID: 32140153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoints and cancer development: Therapeutic implications and future directions.
    Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
    Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications.
    Sivori S; Vacca P; Del Zotto G; Munari E; Mingari MC; Moretta L
    Cell Mol Immunol; 2019 May; 16(5):430-441. PubMed ID: 30778167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of NK Cell Activation by Immune Checkpoint Molecules.
    Beldi-Ferchiou A; Caillat-Zucman S
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29023417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer.
    Cifaldi L; Di Santo J; Olive D
    Front Immunol; 2020; 11():1132. PubMed ID: 32612604
    [No Abstract]   [Full Text] [Related]  

  • 19. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
    Davis ZB; Vallera DA; Miller JS; Felices M
    Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
    Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
    Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.